Sermorelin vs FOXO4-DRI
Head-to-head comparison of Sermorelin and FOXO4-DRI for research applications. Both peptides are studied for Anti-Aging, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Sermorelin | Foxo4 Dri |
|---|---|---|
| Category | Growth Hormone Secretagogue | Senolytic / Anti-Aging |
| Mechanism | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. | Senescent cells survive because FOXO4 protein binds to p53 in the nucleus, sequestering it and preventing p53 from triggering apoptosis. |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical |
| Clinical Status | Previously FDA-approved (Geref, discontinued); now used off-label via compounding | Preclinical. No human clinical trials. Animal studies in aged mice (Baar et al., Cell 2017). |
| Safety Profile | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) | No human safety data exists; Mouse studies used doses of 5 mg/kg via intraperitoneal injection |
| Route | Subcutaneous | Subcutaneous (extrapolated from IP injection in mice) |
| Dose Range | 100–300 mcg/day SC | No established human dose. Mouse studies used 5 mg/kg IP every 3 days for 3 weeks. |
| Frequency | Once daily (typically before bed) | Every 3 days for treatment course (mouse protocol extrapolation) |
| Molecular Weight | ~3357.9 g/mol | N/A |
| Half-Life | ~10–20 minutes | Extended (D-amino acid configuration resists proteolysis) |
Overview
Sermorelin and FOXO4-DRI are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
FOXO4-DRI — Mechanism & Evidence
FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells — aged, dysfunctional "zombie cells" that accumulate in tissues and drive chronic inflammation, tissue dysfunction, and age-related disease. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, causing them to undergo apoptosis while leaving healthy cells unaffected. It is one of the first peptide-based senolytics and has generated significant interest in the longevity research community.
Key claims: Selectively eliminates senescent cells; Reverses age-related vascular decline; Restores testosterone in aged males.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
Sermorelin is also researched for: Body Composition, Sleep.
FOXO4-DRI is also researched for: no additional unique applications.
Safety Considerations
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
FOXO4-DRI: No human safety data exists Mouse studies used doses of 5 mg/kg via intraperitoneal injection Transient weight loss and reduced food intake observed in treated mice
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
CJC-1295 vs Sermorelin: Comparing Growth Hormone-Releasing Peptides
Compare CJC-1295 vs Sermorelin for growth hormone release. Analyze mechanisms, preclinical data, and research limitations for these GHRH analogs.
Tesamorelin vs Sermorelin: Comparing GHRH Analogues in Research
Compare tesamorelin vs sermorelin GHRH analogues for research. Explore mechanisms, preclinical findings, and evidence limitations.
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe